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Acute otitis media (AOM) is a multifactorial disease with a significant socioeconomic
impact. The pathogenesis of AOM is attributed to a variety of well-established internal
and extrinsic factors. Recent evidence strongly points to bacterial biofilm formation as an
important contributor to this disease entity. The nasopharynx is a likely reservoir for infec-
tion with subsequent seeding of pathogens to the middle ear via planktonic shedding.
Various modalities have been used to directly detect biofilm formation in the middle ear
mucosa of children with AOM. Further insights into this disease may lead to new strategies
for prevention and treatment.
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INTRODUCTION AND EPIDEMIOLOGY
PREVALENCE AND SOCIOECONOMIC IMPACT
Otitis media (OM) is one of the most common childhood infec-
tions. Clinically it is characterized by middle ear effusion (MEE)
and recognized as acute otitis media (AOM) or OM with effusion
(OME) (1, 2). OM is the leading reason for visiting the doctor, pre-
scribing antibiotics, and undergoing surgical procedures among
children (1, 3–6).
The peak incidence of AOM is between 6 and 12 months
of age (7, 8). More than 80% of children are diagnosed with
AOM by age 3 (7). National medical expenditures for OM have
been estimated at approximately $4.1 billion for children (9, 10).
While the incidence of OM in the U.S. rose steadily in the latter
part of the twentieth century (8), there has been decline in the
number of pediatric office visits between 1997 and 2007 (11).
Rates of recurrent AOM (RAOM, defined in the study as >3
episodes in the previous 12 months) also declined between 2001
and 2005 (11).
The declining incidence of OM may be attributed to a number
of factors that have been the focus of public health and educa-
tion. The 7-valent pneumococcal conjugate vaccine (PCV7) was
introduced in 2000 and has excellent efficacy against invasive pneu-
mococcal disease (12–14). The “watchful waiting” guidelines aim
to prevent unnecessary physician consultation for mild OM (14).
Reductions in known risk factors such as smoke exposure may
further contribute to the decline (14, 15).
WIDESPREAD ANTIBIOTIC USE AND INCREASING BACTERIAL
RESISTANCE
Use of broad-spectrum antimicrobials in the United States has
increased over the last several decades (15, 16) and is directly
correlated to rising antibiotic resistance (17, 18). Decreasing sus-
ceptibility of invasive S. pneumonia – the most common cause of
pediatric AOM – to penicillin, clindamycin, and macrolides began
in the mid-1990s (15, 19–21).
The serotypes covered by PCV7 were selected to protect against
strains prominent among children worldwide and strains likely
to develop antimicrobial resistance (22). The decrease in preva-
lence of PCV7-related S. pneumoniae has been met with increasing
prevalence of PCV7-unrelated S. pneumoniae (23, 24) and H.
influenzae (4, 25).
Selective pressure from the inappropriate use of antimicrobial
agents is the single greatest factor influencing the spread of resis-
tant S. pneumoniae and other common middle ear pathogens
(15, 18, 20, 23, 25). Despite efforts by the Center for Disease
Control (CDC) to minimize inappropriate use of antimicro-
bials, these practices continue to select for resistant pathogens.
Strict guidelines for the diagnosis and treatment of OM are
imperative.
DIAGNOSIS, SIGNS, AND SYMPTOMS
Children may present with non-specific findings such as ear-
tugging, irritability, fever, or symptoms of a viral illness (3). Symp-
tom duration and severity are not reliable indicators of AOM (3,
26). Accurate diagnosis of AOM requires a thorough examination
of the tympanic membrane (TM) (3).
Recent updates to the AAP/AAFP guidelines for the diagno-
sis and treatment of AOM in children have narrowed down the
diagnostic criteria, particularly in its distinction from OME (3).
Diagnosis requires the presence of MEE with acute onset of signs
and symptoms of middle ear inflammation. MEE is established by
an air-fluid level behind the TM, impaired TM mobility on pneu-
matic otoscopy, or otorrhea signifying TM perforation. AOM is
reliably distinguished from OME by the addition of a “cloudy” and
moderate-to-severe bulging of the TM; less specific signs include
significant TM erythema or hemorrhage (3, 27, 28). Additional
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methods for confirming MEE include tympanometry, acoustic
reflectometry, or tympanocentesis.
RISK FACTORS
HOST
AOM is most common in infancy and early childhood, with peak
incidence between 6 and 12 months of age (7, 8). The immature
state of the immune system in young children predisposes them to
infection, particularly with encapsulated bacteria (29). Incidence
tends to be higher in males (7, 30, 31).
The etiology and pathogenesis of AOM are multifactorial and
represent the interplay between genetic and environmental factors
(11). Twin studies have shown that heritability accounts for 74 and
45% of variation in RAOM incidence in females and males, respec-
tively (29). Several indigenous populations are high-risk for OM:
Native Americans, the Alaskan, Canadian and Greenland Inuit,
and Australian Aborigines (11, 32). Recent availability of genome-
wide association studies (GWAS) has greatly expanded the ability
to search for related genes (30).
The Eustachian tube (ET) helps maintain healthy middle ear
conditions. The ET of infants in relation to their fully matured
anatomy is of a smaller caliber, shorter length, and joins the
nasopharynx at a more acute angle, all of which predispose to
dysfunction of the ET and therefore increased risk of infection
(31, 33). Children with craniofacial anomalies, such as cleft palate
and Trisomy 21, are at increased risk of middle ear disease due
to further ET compromise (34–37). Histopathology studies have
reported deformed ET cartilage (38) and high incidence of OM
(36) in patients with cleft palate.
Some studies have postulated that atopic diseases such aller-
gic rhinitis and asthma can play a role in OM (39). This
may be due to increased susceptibility to invasive pneumococ-
cal disease. However, the exact causal relationship has yet to be
elucidated.
ENVIRONMENT
Upper respiratory tract infections (URTI), both viral and bacte-
rial, have been implicated in the development of AOM due to
mucosal inflammation leading to adenoid hypertrophy, ET dys-
function, and disruption of mucociliary defenses (31, 40, 41).
Virus-mediated inflammatory responses in the middle ear impair
host immunity, promote bacterial colonization and inhibit antimi-
crobial penetration into the middle ear (31, 40). A temporal
relationship is consistently observed with AOM incidence peaking
3–4 days after the onset of URTI symptoms (40).
Exposure to tobacco smoke is well known to adversely affect
the respiratory tract. Higher colonization by pathogenic bacteria
has been demonstrated in the nasopharyngeal flora of smokers
and smoke-exposed children (42). Despite this, studies have not
found a consistent link between smoke exposure and AOM inci-
dence (43, 44). Potential confounding by socioeconomic status,
thought to be inversely correlated with household smoking, often
complicates the interpretation of such studies (43).
The protective effect of breastfeeding on OM incidence has
been reported by the majority of investigators (43, 45). Proposed
explanations for these protective effects have included head posi-
tioning during feeding, exposure to different microorganisms,
improved nutrition and the antibacterial or immunological bene-
fits of breast milk (46).
Exposure to other children, whether at day care or to siblings
at home, is a strong risk factor for OM (11, 31, 43, 44, 46–48).
Specific predictors include attendance by 2 months of age, atten-
dance ≥30 h/week, and day care groups with ≥5 children and ≥2
children 2 years or younger (46).
CLASSICAL THEORY OF PATHOGENESIS
Classical theories of OM pathogenesis describe MEE and subse-
quent infection as direct consequences of ET dysfunction. The ET
preserves normal middle ear conditions through three primary
functions: clearance of middle ear fluid (MEF), ventilation, and
protection from nasopharyngeal reflux (49, 50).
The drainage system of the middle ear is eloquently portrayed
as an inverted flask by Bluestone et al. with the body of the flask
representing the middle ear and the narrow neck representing the
ET (51). The mucociliary wave transports middle ear secretions
toward the nasopharynx. When a precipitating event, such as viral
URTI or allergic rhinitis, triggers nasal mucosal inflammation,
obstruction of the tubal orifice leads to fluid stasis. Individuals
with narrower and horizontally oriented anatomy, cleft palate, or
tensor veli palatini deficiency have impaired drainage and are at
higher risk for MEE (51).
In the open state, the ET ventilates the middle ear and equalizes
pressure with the nasopharynx. This can be done deliberately with
the Valsalva maneuver or palatal elevation via the action of tensor
veli palatini. Studies have reported middle ear gas absorption at a
constant rate of 1 mL/24 h (52, 53), The hydrops ex vacuo theory,
original proposed by Politzer, postulates that continuous nega-
tive middle ear pressure causes transudation of fluid from mucosa
into the middle ear cavity leading to effusion (54). The hydrops ex
vacuo theory has been validated in human studies (55, 56) and is
widely accepted as a key step in the development of MEE.
The et allows greater physical separation between the nasophar-
ynx and middle ear, isolating the middle ear from infection and
offensive material originating from the upper aerodigestive tract.
This is believed to play a role in the higher incidence of OM in
children, who have smaller and more horizontal ET compared
to adults. Higher rates of gastroesophageal reflux, confirmed by
detection of pepsin/pepsinogen in MEF, have been reported in
children with OME or RAOM compared to otherwise healthy chil-
dren (57). Pepsinogen in the middle ear has also been identified
in the adenoids of children with OME, suggesting nasopharyn-
geal reflux as the likely mechanism (58). While some prospective
studies have reported a possible benefit in OM resolution with
antireflux therapy, evidence from large controlled trials is lacking
(57, 59). There are currently no recommendations for the use of
antireflux therapy in treating OM.
THE IMPORTANCE OF BIOFILM PHENOTYPES IN OTITIS
MEDIA
THE CHINCHILLA MODEL
The vast majority of animal models of OM have utilized the chin-
chilla. Giebink cites several factors favoring these animals in the
study of middle ear disease: (1) it is the only animal model in
which S. pneumoniae OM can be induced by inoculation directly
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into the middle ear or nasal cavity, (2) infection rarely spreads
outside of the middle ear, (3) the middle ear is easily accessi-
ble for inoculation and culture, and (4) OM does not naturally
occur in chinchillas (60). Research on chinchilla models, begin-
ning in the 1970s, have contributed to the discovery of potent
S. pneumoniae serotypes (61), identify a role for nasopharyngeal
viral infection in OM pathogenesis, and confirm an immunogenic
response to pneumococcal vaccination (62). Today, the chinchilla
model remains the cornerstone of basic science research in OM.
NASOPHARYNGEAL BACTERIAL COLONIZATION
Nasopharyngeal colonization with potential middle ear pathogens
is regarded as the initial event leading to OM in humans (63, 64).
This theory is strongly supported by work on chinchilla models
(65), which have shown a close correlation between nasopharyn-
geal and middle ear pathogens known to cause AOM (66). At the
same time, children without RAOM carry greater species of benign
nasopharyngeal flora which are thought to inhibit colonization
and proliferation of pathogenic species (67). Many surgeons now
routinely obtain middle meatus or nasopharyngeal cultures in
children with RAOM to identify the causative agents and guide
antimicrobial therapy.
BIOFILMS AND PLANKTONIC SHEDDING
Biofilms are increasingly recognized as a key component of many
chronic and treatment-resistant diseases. Hall-Stoodley et al.
define biofilms as “surface-associated microbial communities sur-
rounded by an extracellular polymeric substance matrix” which
are notoriously resistant to host immune responses and antimicro-
bial therapy (68, 69). Properties of biofilms favoring their survival
include (1) poor antimicrobial penetration, (2) decreased oxygen
and nutrient requirements, (3) increased expression of resistance
genes (e.g., beta-lactamase), and (4) cell-to-cell signaling via quo-
rum sensing (70, 71). The extracellular matrix confers reduced per-
meability to topical and intravenous antimicrobials and along with
other putative resistance mechanisms of biofilms (slower growth
rate, oxygen depleted microenvironment, and other environmen-
tal stresses due to altered physiologic conditions) accounts for
the frequent failure of traditional therapies (70). Quorum sensing
involves intercellular transmission of molecules and genetic infor-
mation which permit coordinated behavior and reaction to the
local environment (71). Extensive research efforts to understand
the biofilm environment have identified a number of therapeutic
targets and will be discussed in the next section.
An overwhelming majority of bacteria in the human body exist
in the biofilm state during which they are extremely difficult to
culture (72). Bacterial biofilms have been implicated in chronic
rhinosinusitis (Staphylococcus aureus) (73), recurrent UTI (E. coli),
and cystic fibrosis pneumonia (Pseudomonas aeruginosa) (68, 71).
It is likely that patients with impaired airway clearance are at higher
risk for biofilm formation (71), although differences in structure
or behavior are unclear. The observation that RAOM often results
in negative MEF cultures and recurs despite appropriate antimi-
crobial therapy has driven the search for biofilms in the middle ear
and nasopharynx (74).
Prior studies using chinchilla models led to direct confirma-
tion of middle ear mucosal biofilms in the setting of OM through
scanning electron microscopy (SEM) (75, 76), and confocal scan-
ning laser microscopy (CSLM) (76). Biofilms were later confirmed
in the middle ear mucosa of children with chronic OM (77, 78),
and on the surface of tympanostomy tubes extracted from children
with RAOM (75) and OME (79). None of these studies identified
significant biofilms in healthy controls, strongly suggesting a role
for biofilms in RAOM pathogenesis. Hoa et al. reported that within
8 days of nasopharyngeal inoculation with influenza A virus and S.
pneumonia in chinchillas, 83% of animals developed nasopharyn-
geal biofilms, 67% developed middle ear biofilms, and all animals
with middle ear biofilms also had nasopharyngeal biofilms (80).
Hoa suggested that the presence of nasopharyngeal biofilms may
be a prerequisite for development of biofilms in the middle ear.
Within the nasopharynx, the adenoids are a likely reservoir for
pathogenic bacterial biofilms (64, 81–83). Adenoid biofilms may
be particularly critical in the pathogenesis of RAOM compared
to OME. Zuliani et al. and Hoa et al. demonstrated significantly
greater biofilm coverage of adenoid mucosa in children with
RAOM compared to children with OME or OSA (81, 82).
A unique feature of biofilms is “planktonic shedding” of bac-
teria from the biofilm surface into the surrounding space, seeding
infection to distant parts of the body in a fashion similar to septic
emboli (81, 84, 85). Planktonic shedding is a continuous process
which appears to escalate during conditions of physiological stress
and starvation, leading Costerton et al. to propose planktonic
shedding as a key survival mechanism of bacterial biofilms (84).
Common pathogens have been found in nasopharyngeal biofilms
and MEEs of children with RAOM (86) and chronic OME (Sheyn
et al., unpublished). These findings are consistent with plank-
tonic shedding from the nasopharynx into the middle ear is a
likely mechanism for RAOM and OME pathogenesis and may
explain the high frequency of negative MEF cultures and frequent
recurrence of these diseases.
DETECTION AND TREATMENT OF BIOFILMS
Commonly used modalities to detect and measure biofilms include
CSLM, SEM, fluorescent in situ hybridization (FISH), lectin-
binding, and immunohistochemical techniques (75–78, 80, 82,
83, 87). These methods require an adequate tissue sample, thus
restricting the study of middle ear biofilms to animal mod-
els and the study of adenoid biofilms to patients undergoing
adenoidectomy, while in vivo studies are all but impossible.
Optical coherence tomography (OCT) is an emerging imaging
modality which may allow non-invasive, in vivo detection of mid-
dle ear biofilms. This technology uses near-infrared laser waves to
penetrate tissue to produce live, three-dimensional images (88), in
a manner similar to ultrasound. However, the shorter wavelength
of near-infrared waves compared to ultrasound waves permits sub-
micrometer resolution. Like ultrasound, OCT is ideal for use in
children because it is well-tolerated, causes no tissue injury, and
avoids radiation exposure. Notably, the depth of penetration is
limited to 1–2 mm due to scattering artifact. OCT has been used
to detect retinal disease in multiple sclerosis (89) and age-related
macular degeneration (90), yet its clinical applications may extend
to a variety of medical fields (91). Nguyen et al recently demon-
strated OCT-based in vivo detection of middle ear biofilms in
adults with chronic OM (92). In a follow-up study, OCT findings
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were directly correlated with acoustic measurements of the TM in a
similar adult population (93). These early studies were limited in
sample size and further investigation is ongoing. OCT remains
a highly promising non-invasive method of detecting biofilms
which may play a role in diagnosing biofilm-related diseases in
the middle ear.
Tympanostomy tubes likely alter middle ear flora by providing
ventilation and increased oxygen tension. The impact on biofilm
behavior is unclear, but may affect detachment rates (94). As a
foreign body, tympanostomy tubes promote biofilm growth in
the setting of initial infection by acting as a scaffold for bacter-
ial colonization and extracellular matrix formation. Tube mate-
rial may be an important factor in biofilm development. An
in vivo animal study found that among several materials, only
ion-bombarded silicone tubes prevented S. aureus biofilm adher-
ence (95), although this effect was not seen with P. aeruginosa
(96). Recently, the protective effect of coated silicone tubes has
been investigated in several in vitro studies. MRSA is inhibited by
vancomycin-coated tubes (97). P. aeruginosa biofilms are inhibited
by polyvinylpyrrolidone (PVP)-coated tubes (98) and piperacillin-
tazobactam coated tubes (99). Silver oxide-coated tubes, which
reduce postoperative otorrhea (100), do not seem to resist biofilms
(97, 99). Further research may lead to culture-directed selection of
coated tympanostomy tubes to eradicate OM. The risk of selecting
for drug resistant strains through low dose antimicrobial therapy
remains a concern.
Middle ear biofilms are not eradicated by commonly prescribed
topical antimicrobials (101). Agents that are effective in treating
upper respiratory tract biofilms, such as mupirocin and gentian
violet (102), are difficult to deliver or potentially ototoxic within
the middle ear. Proposed strategies focus on electromechanical and
biochemical disruption of biofilm adherence and proliferation.
Pulsed laser therapy has been demonstrated to dislodge mid-
dle ear biofilms by generating shockwaves (103). Electromagnetic,
ultrasonic, and photo-therapy may enhance antimicrobial delivery
or activity in certain applications (104).
Biochemical disruption includes identification of specific mol-
ecular targets (87), enhanced drug delivery (104, 105), and dis-
ruption of quorum sensing (105). Drug carriers such as liposomes
(106) and biocompatible polymers (104) may offer a way to
bypass the protective extracellular matrix, allowing penetration
and controlled delivery of antimicrobials directly into the biofilm.
Quorum sensing is a complex process which allows cell-to-
cell communication between biofilm bacteria. Extracellular DNA,
released by cell autolysis, is a method of genetic exchange and is
required for biofilm formation (107). DNase has been studied as
a way to destroy this free-floating DNA and thus inhibit quorum
sensing (108). Alginate lyase targets a key element of the P. aerug-
inosa extracellular matrix and disrupts existing biofilms (109).
Naturally occurring compounds such as bacterial proteins (110)
and tea-tree oil (111) may also possess antibiofilm properties.
Bakaletz described early research on several promising vac-
cines which have shown good efficacy in preventing OM as well
as in vitro studies demonstrating eradication of existing biofilms
(87). The possibility of preventative and therapeutic vaccines to
target middle ear biofilms may dramatically change the landscape
of AOM.
CONCLUSION – IMPLICATION OF BIOFILM INFECTION IN THE
PATHOGENESIS OF OM
Many of these recent studies have demonstrated that RAOM and
COME like many other chronic infections in humans such as
chronic tonsillitis, cholesteatoma, chronic rhinosinusitis, cystic
fibrosis, catheter infections, and infections in implants such as
heart valves may be partially explained by the persistent nature
of biofilm phenotypes. By combining the classical theories of the
pathogenesis of OM with new insights of the nature of biofilms
infections we may be able to develop a more comprehensive
understanding of OM. Indeed biofilms help to explain many pre-
viously documented observations regarding OM, i.e., MEEs that
are culture negative and yet have bacterial RNA identified by PCR,
persistence of middle ear infections despite appropriate level of
therapeutic antibiotics, and the efficacy of low dose antibiotics in
the incidence of RAOM.
Our recent work has evaluated the presence of middle ear
pathogens by utilizing Real Time PCR in the MEF and adenoids
of children with both RAOM and COME. We found that all MEFs
contained middle ear pathogens and that every pathogen identified
in the MEF was also identified in the matched adenoid specimens
(Sheyn et al., unpublished). Although the N-numbers are small,
this work suggests that biofilms may play a role in COME.
The algorithm depicted in Figure 1 combines new concepts
of biofilm infections with classical models of pathogenesis of
OM. In this paradigm, the initial step in the development of
RAOM is the exposure of the nasopharynx to known middle
NP bioﬁlm resistance and AOM recurrence
An"microbials targe"ng planktonic MEPs
Development of ME bioﬁlm by MEPs
Onset of AOM
Entry of free swimming MEPs into ME cavity
ET dysfunc"on crea"ng net nega"ve pressure in ME
Planktonic shedding of MEPs from NP bioﬁlm
Bioﬁlm development on NP mucosa
Forma"on of EPS matrix around MEPs
A#achment and aggrega"on of MEPs in NP
NP exposure to ME pathogens
FIGURE 1 | Proposed algorithm for RAOM pathogenesis.
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ear pathogens followed by colonization and subsequent biofilm
formation by these bacteria. ET dysfunction in otitis prone chil-
dren creates a net negative pressure in the middle ear and allows
planktonically shed middle ear pathogens entry into the middle
ear cavity. This is followed colonization and subsequent biofilm
formation in the middle ear which results in the development
of AOM. This episode of AOM is diagnosed by a primary care
practitioner and is usually treated with a short course of antimi-
crobials. Although the patient may show clinical improvement,
presumably due to effective antibiotic treatment of planktonic
organisms in the middle ear, the nasopharyngeal biofilm remains
resistant and it may again shed planktonic organisms to reinfect the
middle ear cavity, resulting in and thus explaining the recurrence
of AOM.
Research over the past several decades has elucidated anatom-
ical factors important in the pathogenesis of OM in children.
Although there has also been significant research on the identi-
fication of common pathogens including H. influenzae, S. pneu-
moniae, and M. catarrhalis, the mechanisms these pathogens
utilize to colonize and persist in the host have not been well
described. Biofilm phenotypes, as previously discussed, have been
shown to resist host defenses through several mechanisms and
persist despite therapeutic levels of antimicrobials. These char-
acteristics of biofilm infection may help explain recurrent and
persistent nature of many infectious entities. Therefore, a more
comprehensive understanding of the host-organism via biofilm
phenotypes in RAOM and COME expand our knowledge of
the underlying pathogenesis of these recurrent and chronic dis-
ease states. This information could serve as a springboard in
the development of new animal models of OM, new imaging
techniques in diagnosis and novel therapeutic interventions for
treatment.
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